• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Med . Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

tetano

Editor, Senior Moderator
Front Med


. 2020 Oct 5.
doi: 10.1007/s11684-020-0822-5. Online ahead of print.
Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection


Yun Tan[SUP] 1 [/SUP], Feng Liu[SUP] 1 [/SUP], Xiaoguang Xu[SUP] 1 [/SUP], Yun Ling[SUP] 2 [/SUP], Weijin Huang[SUP] 3 [/SUP], Zhaoqin Zhu[SUP] 2 [/SUP], Mingquan Guo[SUP] 2 [/SUP], Yixiao Lin[SUP] 2 [/SUP], Ziyu Fu[SUP] 1 [/SUP], Dongguo Liang[SUP] 1 [/SUP], Tengfei Zhang[SUP] 2 [/SUP], Jian Fan[SUP] 2 [/SUP], Miao Xu[SUP] 3 [/SUP], Hongzhou Lu[SUP] 4 [/SUP], Saijuan Chen[SUP] 5 [/SUP]



Affiliations

Abstract

The ongoing pandemic of Coronavirus disease 19 (COVID-19) is caused by a newly discovered β Coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How long the adaptive immunity triggered by SARS-CoV-2 can last is of critical clinical relevance in assessing the probability of second infection and efficacy of vaccination. Here we examined, using ELISA, the IgG antibodies in serum specimens collected from 17 COVID-19 patients at 6-7 months after diagnosis and the results were compared to those from cases investigated 2 weeks to 2 months post-infection. All samples were positive for IgGs against the S- and N-proteins of SARS-CoV-2. Notably, 14 samples available at 6-7 months post-infection all showed significant neutralizing activities in a pseudovirus assay, with no difference in blocking the cell-entry of the 614D and 614G variants of SARS-CoV-2. Furthermore, in 10 blood samples from cases at 6-7 months post-infection used for memory T-cell tests, we found that interferon γ-producing CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] cells were increased upon SARS-CoV-2 antigen stimulation. Together, these results indicate that durable anti-SARS-CoV-2 immunity is common in convalescent population, and vaccines developed from 614D variant may offer protection from the currently predominant 614D variant of SARS-CoV-2.

Keywords: SARS-CoV-2; T-cell response; neutralizing antibodies.
 
Back
Top Bottom